IDH2 and neoplasm: The independent clinical utility of assessing for ATRX status by immunohistochemistry in adults is unclear, especially considering that sequencing and/or methylation profiling would typically be required to confirm less common tumor diagnoses in the IDH-wt setting that may harbor ARTX alterations.